Lde,Dde,P15,P16,P17,P18,P19,P20,P1,P22,P23,Source-Prop-Ent
Bridging the Expertise of Advocates and Academics to Identify Reproductive Justice Learning Outcomes,Publikation,"Loder CM, Minadeo L, Jimenez L, Luna Z, Ross L, Rosenbloom N, Stalburg CM, Harris LH",Teach Learn Med,Jan-Mar;32(1):11-22,+2020-01-01T00:00:00Z/9,10.1080/10401334.2019.1631168,Reproductive justice; advocacy; curriculum development; health disparities,https://pubmed.ncbi.nlm.nih.gov/31293184/,Sterilisation von intergeschlechtlichen Personen (meist unfreiwillig),Geschlecht,"P3"
Sex definitions and gender practices. An update from Australia,Publikation,Cregan K,Camb Q Healthc Ethics,Jul;23(3):319-25,+2014-01-01T00:00:00Z/9,10.1017/S0963180113000923,,https://pubmed.ncbi.nlm.nih.gov/24867337/,Sterilisation von intergeschlechtlichen Personen (meist unfreiwillig),Geschlecht,"P3"
THE TREATMENT OF INTERSEX AND THE PROBLEM OF DELAY: THE AUSTRALIAN SENATE INQUIRY INTO INTERSEX SURGERY AND CONFLICTING HUMAN RIGHTS FOR CHILDREN,Publikation,O'Connor M,J Law Med.,Mar;23(3):531-43,+2016-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/27323632/,Sterilisation von intergeschlechtlichen Personen (meist unfreiwillig),Geschlecht,"P3"
The human rights of intersex people: addressing harmful practices and rhetoric of change,Publikation,Carpenter M,Reprod Health Matters,May;24(47):74-84,+2016-01-01T00:00:00Z/9,10.1016/j.rhm.2016.06.003,disorders of sex development; harmful practices; hermeneutical injustice; human rights; intersex,https://pubmed.ncbi.nlm.nih.gov/27578341/,Sterilisation von intergeschlechtlichen Personen (meist unfreiwillig),Geschlecht,"P3"
Disorders of Sexual Differentiation: Ethical Considerations Surrounding Early Cosmetic Genital Surgery,Publikation,Anderson S,Pediatr Nurs,Jul-Aug;41(4):176-86,+2015-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/26470466/,Sterilisation von intergeschlechtlichen Personen (meist unfreiwillig),Geschlecht,"P3"
Queering reproductive access: reproductive justice in assisted reproductive technologies,Publikation,Tam MW,Reprod Health,Aug 2;18(1):164,+2021-01-01T00:00:00Z/9,10.1186/s12978-021-01214-8,,https://pubmed.ncbi.nlm.nih.gov/34340704/,Sterilisation von intergeschlechtlichen Personen (meist unfreiwillig),Geschlecht,"P3"
Vasectomy,Publikation,"Edwards IS, Farlow JL",Med J Aust,Jan 12;1(1):39,+1980-01-01T00:00:00Z/9,10.5694/j.1326-5377.1980.tb134598.x,,https://pubmed.ncbi.nlm.nih.gov/7360080/,Sterilisation des Mannes (Vasektomie),Effizienzmaße,P9
Microrecanalization after vasectomy in man,Publikation,"Freund MJ, Weidmann JE, Goldstein M, Marmar J, Santulli R, Oliveira N",J Androl,Mar-Apr;10(2):120-32,+1989-01-01T00:00:00Z/9,10.1002/j.1939-4640.1989.tb00073.x,,https://pubmed.ncbi.nlm.nih.gov/2715100/,Sterilisation des Mannes (Vasektomie),Effizienzmaße,P9
Fatherhood without apparent spermatozoa after vasectomy,Publikation,"Smith JC, Cranston D, O'Brien T, Guillebaud J, Hindmarsh J, Turner AG",Lancet,Jul 2;344(8914):30,+1994-01-01T00:00:00Z/9,10.1016/s0140-6736(94)91052-9,,https://pubmed.ncbi.nlm.nih.gov/7912302/,Sterilisation des Mannes (Vasektomie),Effizienzmaße,P9
Evaluation of one-hundred open-ended vasectomies,Publikation,"Temmerman M, Cammu H, Devroey P, Amy JJ",Contraception,Jun;33(6):529-32,+1986-01-01T00:00:00Z/9,10.1016/0010-7824(86)90040-5,,https://pubmed.ncbi.nlm.nih.gov/3769480/,Sterilisation des Mannes (Vasektomie),Effizienzmaße,P9
Paternity after vasectomy with two previous semen analyses without spermatozoa,Publikation,"Lucon M, Lucon AM, Pasqualoto FF, Srougi M",Sao Paulo Med J,Mar 1;125(2):122-3,+2007-01-01T00:00:00Z/9,10.1590/s1516-31802007000200011,,https://pubmed.ncbi.nlm.nih.gov/17625712/,Sterilisation des Mannes (Vasektomie),Effizienzmaße,P9
Vasectomy: Current information,Publikation,"Kreutzig-Langenfeld T, Lellig E, Hinz P, Zilg F",Urologe A,Apr;60(4):523-532,+2021-01-01T00:00:00Z/9,10.1007/s00120-021-01494-9,Contraception; Contraception without side effects; Fertility; Hormone-free contraception; Men; No-scalpel vasectomy; Sterilization,https://pubmed.ncbi.nlm.nih.gov/33738559/,Sterilisation des Mannes (Vasektomie),Geschlecht,"P3"
Vasectomy occlusion techniques for male sterilization,Publikation,"Cook LA, Van Vliet HA, Lopez LM, Pun A, Gallo MF",Cochrane Database Syst Rev,Mar 30;2014(3):CD003991,+2014-01-01T00:00:00Z/9,10.1002/14651858.CD003991.pub4,,https://pubmed.ncbi.nlm.nih.gov/24683020/,Sterilisation des Mannes (Vasektomie),Material des Verhütungsmittels,P5
"Outpatient Vasectomy: Safe, Reliable, and Cost-effective",Publikation,"Zeitler M, Rayala B",Prim Care,Dec;48(4):613-625,+2021-01-01T00:00:00Z/9,10.1016/j.pop.2021.08.001,Contraception; Outpatient; Safety; Vasectomy,https://pubmed.ncbi.nlm.nih.gov/34752273/,Sterilisation des Mannes (Vasektomie),Material des Verhütungsmittels,P5
Vasectomy reversal,Publikation,Practice Committee of American Society for Reproductive Medicine,Fertil Steril,Nov;90(5 Suppl):S78-82,+2008-01-01T00:00:00Z/9,10.1016/j.fertnstert.2008.08.097,,https://pubmed.ncbi.nlm.nih.gov/19007653/,Sterilisation des Mannes (Vasektomie),Material des Verhütungsmittels,P5
Current status of vasectomy reversal,Publikation,"Schwarzer JU, Steinfatt H",Nat Rev Urol,Apr;10(4):195-205,+2013-01-01T00:00:00Z/9,10.1038/nrurol.2013.14,,https://pubmed.ncbi.nlm.nih.gov/23399733/,Sterilisation des Mannes (Vasektomie),Material des Verhütungsmittels,P5
Is there a place for tubal ligation in modern contraception?,Publikation,"von Mering R, Merki GS, Keller P",Gynakol Geburtshilfliche Rundsch,Jan;43(1):25-30,+2003-01-01T00:00:00Z/9,10.1159/000067166,,https://pubmed.ncbi.nlm.nih.gov/12499754/,Sterilisation der Frau (Tubenligatur),Geschlecht,"P3"
FSFI score and timing of tubal ligation in patients: preliminary results of an online survey,Publikation,"Walter S, Upadhjay M, Beslic J, Pucher M, Herbel R, Stavroula S, Dayan D, Janni W, Ebner F",Arch Gynecol Obstet,Sep;306(3):795-800,+2022-01-01T00:00:00Z/9,10.1007/s00404-022-06547-8,FSFI; Regretting; Sterilisation; Tubal ligation,https://pubmed.ncbi.nlm.nih.gov/35397718/,Sterilisation der Frau (Tubenligatur),Geschlecht,"P3"
Salpingectomy vs tubal ligation for sterilization: a systematic review and meta-analysis,Publikation,"Mills K, Marchand G, Sainz K, Azadi A, Ware K, Vallejo J, Anderson S, King A, Osborn A, Ruther S, Brazil G, Cieminski K, Hopewell S, Rials L, Klipp A",Am J Obstet Gynecol,Mar;224(3):258-265.e4,+2021-01-01T00:00:00Z/9,10.1016/j.ajog.2020.09.011,risk-reducing salpingectomy; risk-reducing surgery; salpingectomy; sterilization; surgery to reduce the risk of ovarian cancer; tubal ligation,https://pubmed.ncbi.nlm.nih.gov/32941790/,Sterilisation der Frau (Tubenligatur),Material des Verhütungsmittels,P5
Vaginal tubal ligation,Publikation,Stephens DB,South Med J,Dec;73(12):1578-80,+1980-01-01T00:00:00Z/9,10.1097/00007611-198012000-00012,,https://pubmed.ncbi.nlm.nih.gov/7444547/,Sterilisation der Frau (Tubenligatur),Effizienzmaße,P9
Cost and efficacy comparison of in vitro fertilization and tubal anastomosis for women after tubal ligation,Publikation,"Messinger LB, Alford CE, Csokmay JM, Henne MB, Mumford SL, Segars JH, Armstrong AY",Fertil Steril,Jul;104(1):32-8.e4,+2015-01-01T00:00:00Z/9,10.1016/j.fertnstert.2015.04.019,In vitro fertilization (IVF); bilateral tubal anastomosis (BTA); cost effectiveness; decision tree; tubal reversal,https://pubmed.ncbi.nlm.nih.gov/26006734/,Sterilisation der Frau (Tubenligatur),Material des Verhütungsmittels,P5
Tubal ligation on an unmarried girl: How and why?,Publikation,Saldanha S,Indian J Med Ethics,Apr-Jun;1(2):116-7,+2016-01-01T00:00:00Z/9,10.20529/IJME.2016.031,,https://pubmed.ncbi.nlm.nih.gov/27260823/,Sterilisation der Frau (Tubenligatur),Geschlecht,"P3"
Tubal ligation with local anaesthesia,Publikation,Barss P,Trop Doct,Oct;15(4):175-9,+1985-01-01T00:00:00Z/9,10.1177/004947558501500410,,https://pubmed.ncbi.nlm.nih.gov/4049507/,Sterilisation der Frau (Tubenligatur),Material des Verhütungsmittels,P5
Patient education. Tubal ligation,Publikation,Murtagh J,Aust Fam Physician,Apr;22(4):611,+1993-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8481125/,Sterilisation der Frau (Tubenligatur),Geschlecht,"P3"
Permanent Contraception for Women,Publikation,"Patil E, Jensen JT",Semin Reprod Med,May;34(3):139-44,+2016-01-01T00:00:00Z/9,10.1055/s-0036-1571434,,https://pubmed.ncbi.nlm.nih.gov/26960907/,Sterilisation der Frau (Tubenligatur),Geschlecht,"P3"
Female permanent contraception trends and updates,Publikation,"Fang NZ, Advaney SP, Castaño PM, Davis A, Westhoff CL",Am J Obstet Gynecol,Jun;226(6):773-780,+2022-01-01T00:00:00Z/9,10.1016/j.ajog.2021.12.261,female sterilization; permanent contraception; postpartum sterilization; tubal ligation,https://pubmed.ncbi.nlm.nih.gov/34973178/,Sterilisation der Frau (Tubenligatur),Geschlecht,"P3"
Comparing options for females seeking permanent contraception in high resource countries: a systematic review,Publikation,"Gormley R, Vickers B, Cheng B, Norman WV",Reprod Health,Jul 20;18(1):154,+2021-01-01T00:00:00Z/9,10.1186/s12978-021-01201-z,Hysteroscopic tubal occlusion; Laparoscopic tubal ligation; Levonorgestrel intrauterine contraceptive; Permanent contraception; Salpingectomy; Systematic review,https://pubmed.ncbi.nlm.nih.gov/34284794/,Sterilisation der Frau (Tubenligatur),Effizienzmaße,P9
Comparative Effectiveness and Safety of Intrauterine Contraception and Tubal Ligation,Publikation,"Schwarz EB, Lewis CA, Dove MS, Murphy E, Zuckerman D, Nunez-Eddy C, Tancredi DJ, McDonald-Mosley R, Sonalkar S, Hathaway M, Gariepy AM",J Gen Intern Med,Dec;37(16):4168-4175,+2022-01-01T00:00:00Z/9,10.1007/s11606-022-07433-4,Medicaid; comparative effectiveness; disparities; female sterilization; intrauterine contraception; low income; permanent contraception; reproductive justice; tubal ligation,https://pubmed.ncbi.nlm.nih.gov/35194746/,Sterilisation der Frau (Tubenligatur),Effizienzmaße,P9
Sperm transport and survival post-application of a new spermicide contraceptive. Advantage 24 Study Group,Publikation,"Sangi-Haghpeykar H, Poindexter AN 3rd, Levine H",Contraception,Jun;53(6):353-6,+1996-01-01T00:00:00Z/9,10.1016/0010-7824(96)00084-4,,https://pubmed.ncbi.nlm.nih.gov/8773422/,Spermizid,Effizienzmaße,P9
A randomized crossover trial of the impact of additional spermicide on condom failure rates,Publikation,"Gabbay MB, Thomas J, Gibbs A, Hold P",Sex Transm Dis,Oct;35(10):862-8,+2008-01-01T00:00:00Z/9,10.1097/OLQ.0b013e31817fb802,,https://pubmed.ncbi.nlm.nih.gov/18685543/,Spermizid,Effizienzmaße,P9
"Combining a synthetic spermicide with a natural trichomonacide for safe, prophylactic contraception",Publikation,"Jain A, Kumar L, Kushwaha B, Sharma M, Pandey A, Verma V, Sharma V, Singh V, Rawat T, Sharma VL, Maikhuri JP, Gupta G",Hum Reprod,Feb;29(2):242-52,+2014-01-01T00:00:00Z/9,10.1093/humrep/det423,DSE-37; Sapindus saponins; Trichomonas vaginalis; spermicide; vaginal contraception,https://pubmed.ncbi.nlm.nih.gov/24291662/,Spermizid,Material des Verhütungsmittels,P5
AF-2364 is a prospective spermicide candidate,Publikation,"Wang H, Chen XX, Wang LR, Mao YD, Zhou ZM, Sha JH",Asian J Androl,May;12(3):322-35,+2010-01-01T00:00:00Z/9,10.1038/aja.2010.11,,https://pubmed.ncbi.nlm.nih.gov/20418891/,Spermizid,Material des Verhütungsmittels,P5
Spermicide used alone for contraception,Publikation,"Grimes DA, Lopez LM, Raymond EG, Halpern V, Nanda K, Schulz KF",Cochrane Database Syst Rev,Sep 30;(9):CD005218,+2013-01-01T00:00:00Z/9,10.1002/14651858.CD005218.pub3,,https://pubmed.ncbi.nlm.nih.gov/24085632/,Spermizid,Geschlecht,"P3"
Update on nonoxynol-9 as vaginal spermicide,Publikation,"Iyer V, Poddar SS",Eur J Contracept Reprod Health Care,Dec;13(4):339-50,+2008-01-01T00:00:00Z/9,10.1080/13625180802263515,,https://pubmed.ncbi.nlm.nih.gov/19117251/,Spermizid,Material des Verhütungsmittels,P5
dl-Mandelic acid exhibits high sperm-immobilizing activity and low vaginal irritation: A potential non-surfactant spermicide for contraception,Publikation,"Xia M, Yang M, Wang Y, Tian F, Hu J, Yang W, Tao S, Lu L, Ding X, Jiang S, Li W",Biomed Pharmacother,Jun;126:110104,+2020-01-01T00:00:00Z/9,10.1016/j.biopha.2020.110104,Immobilization; Mandelic acid; Spermicide; Vaginal irritation,https://pubmed.ncbi.nlm.nih.gov/32224371/,Spermizid,Material des Verhütungsmittels,P5
Spermicide use and pregnancy outcome,Publikation,"Strobino B, Kline J, Warburton D",Am J Public Health,Mar;78(3):260-3,+1988-01-01T00:00:00Z/9,10.2105/ajph.78.3.260,,https://pubmed.ncbi.nlm.nih.gov/3341493/,Spermizid,Effizienzmaße,P9
The effectiveness of barrier methods of contraception with and without spermicide. Contraception,Publikation,"Craig S, Hepburn S",Contraception,Oct;26(4):347-59,+1982-01-01T00:00:00Z/9,10.1016/0010-7824(82)90102-0,,https://pubmed.ncbi.nlm.nih.gov/6759027/,Spermizid,Effizienzmaße,P9
"Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users",Publikation,"Bodner K, Bodner-Adler B, Grünberger W",Arch Gynecol Obstet,Mar;283(3):525-30,+2011-01-01T00:00:00Z/9,10.1007/s00404-010-1368-6,,https://pubmed.ncbi.nlm.nih.gov/20111970/,Hormonpflaster,Effizienzmaße,P9
Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch,Publikation,"Sonnenberg FA, Burkman RT, Speroff L, Westhoff C, Hagerty CG",Am J Obstet Gynecol,Jan;192(1):1-9,+2005-01-01T00:00:00Z/9,10.1016/j.ajog.2004.09.004,,https://pubmed.ncbi.nlm.nih.gov/15671994/,Hormonpflaster,Effizienzmaße,P9
An evaluation of the use of the transdermal contraceptive patch in adolescents,Publikation,"Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr",J Adolesc Health,May;34(5):395-401,+2004-01-01T00:00:00Z/9,10.1016/j.jadohealth.2003.08.017,,https://pubmed.ncbi.nlm.nih.gov/15093794/,Hormonpflaster,Effizienzmaße,P9
Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions,Publikation,"Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW",Fertil Steril,Feb;77(2 Suppl 2):S32-5,+2002-01-01T00:00:00Z/9,10.1016/s0015-0282(01)03262-9,,https://pubmed.ncbi.nlm.nih.gov/11849634/,Hormonpflaster,Material des Verhütungsmittels,P5
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study,Publikation,"Kaunitz AM, Portman D, Westhoff CL, Mishell DR Jr, Archer DF, Foegh M",Contraception,Mar;91(3):211-6,+2015-01-01T00:00:00Z/9,10.1016/j.contraception.2014.11.013,Adhesiveness; Ethinyl estradiol; Itching; Levonorgestrel; Transdermal patch,https://pubmed.ncbi.nlm.nih.gov/25586864/,Hormonpflaster,Material des Verhütungsmittels,P5
"Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life",Publikation,"Sanga M, Vaughan S, Nangosyah J, Scholz V, Fonseca S",Int J Clin Pharmacol Ther,Jan;60(1):67-78,+2022-01-01T00:00:00Z/9,10.5414/CP204034,,https://pubmed.ncbi.nlm.nih.gov/34779392/,Hormonpflaster,Material des Verhütungsmittels,P5
A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch,Publikation,Graziottin A,Treat Endocrinol,5(6):359-65,+2006-01-01T00:00:00Z/9,10.2165/00024677-200605060-00004,,https://pubmed.ncbi.nlm.nih.gov/17107221/,Hormonpflaster,Geschlecht,"P3"
The transdermal contraceptive patch: an updated review of the literature,Publikation,"O'Connell K, Burkman RT",Clin Obstet Gynecol,Dec;50(4):918-26,+2007-01-01T00:00:00Z/9,10.1097/GRF.0b013e318159c410,,https://pubmed.ncbi.nlm.nih.gov/17982334/,Hormonpflaster,Geschlecht,"P3"
The progestogen-only mini-pill,Publikation,"Graham S, Fraser IS",Contraception,Oct;26(4):373-88,+1982-01-01T00:00:00Z/9,10.1016/0010-7824(82)90104-4,,https://pubmed.ncbi.nlm.nih.gov/6759029/,Gestagenpille (Minipille),Geschlecht,"P3"
A study of women on the progestogen only pill,Publikation,Robertson MC,Practitioner,Apr;228(1390):435-9,+1984-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/6728816/,Gestagenpille (Minipille),Geschlecht,"P3"
"A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day",Publikation,,Eur J Contracept Reprod Health Care,Dec;3(4):169-78,+1998-01-01T00:00:00Z/9,10.3109/13625189809167250,,https://pubmed.ncbi.nlm.nih.gov/10036599/,Gestagenpille (Minipille),Effizienzmaße,P10
Clinical experience with the progestogen-only pill,Publikation,"Broome M, Fotherby K",Contraception,Nov;42(5):489-95,+1990-01-01T00:00:00Z/9,10.1016/0010-7824(90)90077-9,,https://pubmed.ncbi.nlm.nih.gov/2125544/,Gestagenpille (Minipille),Effizienzmaße,P10
The progestogen-only pill,Publikation,Howie PW,Br J Obstet Gynaecol,Oct;92(10):1001-2,+1985-01-01T00:00:00Z/9,10.1111/j.1471-0528.1985.tb02993.x,,https://pubmed.ncbi.nlm.nih.gov/3840384/,Gestagenpille (Minipille),Effizienzmaße,P7
A review of the effectiveness of a progestogen-only pill containing norgestrel 75 µg/day,Publikation,"Glasier A, Sober S, Gasloli R, Goyal A, Laurora I",Contraception,Jan;105:1-6,+2022-01-01T00:00:00Z/9,10.1016/j.contraception.2021.08.016,,https://pubmed.ncbi.nlm.nih.gov/34499877/,Gestagenpille (Minipille),Effizienzmaße,P7
Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake,Publikation,"Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S",Contraception,Apr;93(4):303-309,+2016-01-01T00:00:00Z/9,10.1016/j.contraception.2015.12.007,,https://pubmed.ncbi.nlm.nih.gov/26708301/,Gestagenpille (Minipille),Effizienzmaße,P9
Mechanism of action of norgestrel 0.075 mg a progestogen-only pill. I. Effect on ovarian activity,Publikation,"Glasier A, Edelman A, Creinin MD, Han L, Matulich MC, Brache V, Westhoff CL, Hemon A",Contraception,Aug;112:37-42,+2022-01-01T00:00:00Z/9,10.1016/j.contraception.2022.03.022,Contraception; Hoogland score; Ovulation; Pharmacodynamics; Progestogen-only pills,https://pubmed.ncbi.nlm.nih.gov/35351445/,Gestagenpille (Minipille),Effizienzmaße,P9
"Interest in over-the-counter progestin-only pills among transgender, nonbinary, and gender-expansive individuals in the United States",Publikation,"Grindlay K, Obedin-Maliver J, Ragosta S, Hastings J, Lunn MR, Flentje A, Capriotti MR, Dastur Z, Lubensky ME, Moseson H",Am J Obstet Gynecol,Jun;230(6):657.e1-657.e17,+2024-01-01T00:00:00Z/9,10.1016/j.ajog.2024.02.006,LGBTQ+ health; contraception; equity; equity: gender expression or identity; equity: sexual orientation; family planning; health disparities; health policy and health economics; transgender patient care,https://pubmed.ncbi.nlm.nih.gov/38365096/,Gestagenpille (Minipille),Geschlecht,"P3"
Vaginal ring contraception,Publikation,"Kerns J, Darney P",Contraception,Feb;83(2):107-15,+2011-01-01T00:00:00Z/9,10.1016/j.contraception.2010.07.008,,https://pubmed.ncbi.nlm.nih.gov/21237335/,Vaginalring,Geschlecht,"P3"
Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world,Publikation,"Ridgeway K, Montgomery ET, Smith K, Torjesen K, van der Straten A, Achilles SL, Griffin JB",Contraception,Feb;106:16-33,+2022-01-01T00:00:00Z/9,10.1016/j.contraception.2021.10.001,Acceptability; Contraception; HIV prevention; Meta-analysis; Systematic review; Vaginal ring,https://pubmed.ncbi.nlm.nih.gov/34644609/,Vaginalring,Geschlecht,"P3"
The contraceptive vaginal ring,Publikation,"Edwardson J, Jamshidi R",Semin Reprod Med,Mar;28(2):133-9,+2010-01-01T00:00:00Z/9,10.1055/s-0030-1248138,,https://pubmed.ncbi.nlm.nih.gov/20352563/,Vaginalring,Geschlecht,"P3"
The vaginal ring (NuvaRing®) for contraception in adolescent women,Publikation,Bitzer J,Gynecol Endocrinol,Feb;28(2):125-9,+2012-01-01T00:00:00Z/9,10.3109/09513590.2011.579665,,https://pubmed.ncbi.nlm.nih.gov/21615237/,Vaginalring,Geschlecht,"P3"
Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel,Publikation,"Elkik F, Basdevant A, Jackanicz TM, Guy-Grand B, Mercier-Bodard C, Conard J, Bardin CW, Corvol P",J Clin Endocrinol Metab,Jul;63(1):29-35,+1986-01-01T00:00:00Z/9,10.1210/jcem-63-1-29,,https://pubmed.ncbi.nlm.nih.gov/3086360/,Vaginalring,Material des Verhütungsmittels,P5
Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol,Publikation,"Olsson SE, Odlind V",Contraception,Nov;42(5):563-72,+1990-01-01T00:00:00Z/9,10.1016/0010-7824(90)90083-8,,https://pubmed.ncbi.nlm.nih.gov/2272184/,Vaginalring,Material des Verhütungsmittels,P5
Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate,Publikation,"Mishell DR Jr, Talas M, Parlow AF, Moyer DL",Am J Obstet Gynecol,May 1;107(1):100-7,+1970-01-01T00:00:00Z/9,10.1016/s0002-9378(16)33897-2,,https://pubmed.ncbi.nlm.nih.gov/5443056/,Vaginalring,Material des Verhütungsmittels,P5
Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis,Publikation,"López-Picado A, Lapuente O, Lete I",Eur J Contracept Reprod Health Care,Apr;22(2):131-146,+2017-01-01T00:00:00Z/9,10.1080/13625187.2017.1287351,Contraceptive vaginal ring; meta-analysis; oral contraceptives; systematic review,https://pubmed.ncbi.nlm.nih.gov/28256919/,Vaginalring,Effizienzmaße,P9
Evaluating the efficacy and safety of a progestin- and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring,Publikation,"Nguyen BT, Jensen JT",Expert Opin Drug Saf,Oct;13(10):1423-30,+2014-01-01T00:00:00Z/9,10.1517/14740338.2014.948842,combined contraceptive vaginal ring; contraception; contraceptive failure; deep vein thrombosis; safety; venous thromboembolism,https://pubmed.ncbi.nlm.nih.gov/25106828/,Vaginalring,Effizienzmaße,P9
"Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing",Publikation,Roumen F,Eur J Contracept Reprod Health Care,Dec;7 Suppl 2:19-24; discussion 37-9,+2002-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/12659398/,Vaginalring,Effizienzmaße,P9
"Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol",Publikation,"Roumen FJ, Apter D, Mulders TM, Dieben TO",Hum Reprod,Mar;16(3):469-75,+2001-01-01T00:00:00Z/9,10.1093/humrep/16.3.469,,https://pubmed.ncbi.nlm.nih.gov/11228213/,Vaginalring,Effizienzmaße,P9
"Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring",Publikation,"Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, Nash HA",Contraception,May;59(5):311-8,+1999-01-01T00:00:00Z/9,10.1016/s0010-7824(99)00035-9,,https://pubmed.ncbi.nlm.nih.gov/10494485/,Vaginalring,Effizienzmaße,P9
Depot-medroxyprogesterone acetate: an update,Publikation,"Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F",Arch Gynecol Obstet,Jul;278(1):1-12,+2008-01-01T00:00:00Z/9,10.1007/s00404-007-0497-z,,https://pubmed.ncbi.nlm.nih.gov/18470526/,Dreimonatsspritze,Geschlecht,"P3"
Depot medroxyprogesterone acetate contraception in women with medical problems,Publikation,Frederiksen MC,J Reprod Med,May;41(5 Suppl):414-8,+1996-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8725704/,Dreimonatsspritze,Geschlecht,"P3"
The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review,Publikation,"Dragoman MV, Gaffield ME",Contraception,Sep;94(3):202-15,+2016-01-01T00:00:00Z/9,10.1016/j.contraception.2016.02.003,DMPA; Depot medroxyprogesterone; Progestogen-only injectables; Safety; Subcutaneous,https://pubmed.ncbi.nlm.nih.gov/26874275/,Dreimonatsspritze,Geschlecht,"P3"
Pharmacokinetics of depot medroxyprogesterone acetate contraception,Publikation,Mishell DR Jr,J Reprod Med,May;41(5 Suppl):381-90,+1996-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8725700/,Dreimonatsspritze,Material des Verhütungsmittels,P5
Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety,Publikation,Westhoff C,Contraception,Aug;68(2):75-87,+2003-01-01T00:00:00Z/9,10.1016/s0010-7824(03)00136-7,,https://pubmed.ncbi.nlm.nih.gov/12954518/,Dreimonatsspritze,Effizienzmaße,P9
Long-acting injectable contraception with depot medroxyprogesterone acetate,Publikation,Kaunitz AM,Am J Obstet Gynecol,May;170(5 Pt 2):1543-9,+1994-01-01T00:00:00Z/9,,,://pubmed.ncbi.nlm.nih.gov/8178904/,Dreimonatsspritze,Effizienzmaße,P9
A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg,Publikation,"Said S, Omar K, Koetsawang S, Kiriwat O, Srisatayapan Y, Kazi A, Ajmal F, Wynter HH, Pretnar-Darovec A, Benitez IB, et al",Contraception,Sep;34(3):223-35,+1986-01-01T00:00:00Z/9,10.1016/0010-7824(86)90004-1,,https://pubmed.ncbi.nlm.nih.gov/2947777/,Dreimonatsspritze,Effizienzmaße,P9
Levonorgestrel IUD: is there a long-lasting effect on return to fertility?,Publikation,"Dinehart E, Lathi RB, Aghajanova L",J Assist Reprod Genet,Jan;37(1):45-52,+2020-01-01T00:00:00Z/9,10.1007/s10815-019-01624-5,Copper IUD; Endometrial gene expression; Infertility; Intrauterine device; LNG-IUD; Levonorgestrel,https://pubmed.ncbi.nlm.nih.gov/31709489/,Hormonspirale,Material des Verhütungsmittels,P5
"Hormonal IUD is the major hormonal contraceptive method used among women aged 40-49 years: Data from the 2015-16 Tromsø Study, Norway",Publikation,"Bjørkås M, Skjeldestad FE",Eur J Obstet Gynecol Reprod Biol,Jan;280:93-97,+2023-01-01T00:00:00Z/9,10.1016/j.ejogrb.2022.11.019,Combined oral contraceptives; Hormonal contraceptives; Hormonal injection; Hormonal intrauterine device; Hormonal patch; Implants; Premenopausal women; Progestogen-only pills,https://pubmed.ncbi.nlm.nih.gov/36442379/,Hormonspirale,Geschlecht,"P3"
Ovarian function after seven years' use of a levonorgestrel IUD,Publikation,"Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E",Adv Contracept,Jun;11(2):85-95,+1995-01-01T00:00:00Z/9,10.1007/BF01987274,,https://pubmed.ncbi.nlm.nih.gov/7491859/,Hormonspirale,Effizienzmaße,P9
Lost levonorgestrel IUD: diagnosis and therapy,Publikation,"Nitke S, Rabinerson D, Dekel A, Sheiner E, Kaplan B, Hackmon R",Contraception,Apr;69(4):289-93,+2004-01-01T00:00:00Z/9,10.1016/j.contraception.2003.11.017,,https://pubmed.ncbi.nlm.nih.gov/15033403/,Hormonspirale,Effizienzmaße,P9
Comparative safety and efficacy of a dedicated postpartum IUD inserter versus forceps for immediate postpartum IUD insertion: a randomized trial,Publikation,"Blumenthal PD, Lerma K, Bhamrah R, Singh S; Dedicated PPIUD Inserter Working Group",Contraception,Sep;98(3):215-219,+2018-01-01T00:00:00Z/9,10.1016/j.contraception.2018.04.019,IUD; LARC; PPIUD; Postpartum contraception,https://pubmed.ncbi.nlm.nih.gov/29750926/,Hormonspirale,Material des Verhütungsmittels,P5
Risk factors for IUD failure: results of a large multicentre case-control study,Publikation,"Thonneau P, Almont T, de La Rochebrochard E, Maria B",Hum Reprod,Oct;21(10):2612-6,+2006-01-01T00:00:00Z/9,10.1093/humrep/del208,,https://pubmed.ncbi.nlm.nih.gov/16775156/,Hormonspirale,Effizienzmaße,P9
An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs,Publikation,Chi IC,Contraception,Dec;44(6):573-88,+1991-01-01T00:00:00Z/9,10.1016/0010-7824(91)90078-t,,https://pubmed.ncbi.nlm.nih.gov/1773615/,Hormonspirale,Material des Verhütungsmittels,P5
Ovarian function during use of a levonorgestrel-releasing IUD,Publikation,"Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED",Contraception,Jul;42(1):51-66,+1990-01-01T00:00:00Z/9,10.1016/0010-7824(90)90092-a,,https://pubmed.ncbi.nlm.nih.gov/2117516/,Hormonspirale,Effizienzmaße,P9
Contraceptive efficacy of the Copper T380A and the Multiload Cu250 IUD in three developing countries,Publikation,"Farr G, Amatya R",Adv Contracept,Jun;10(2):137-49,+1994-01-01T00:00:00Z/9,10.1007/BF01978107,,https://pubmed.ncbi.nlm.nih.gov/7942261/,Kupferspirale,Effizienzmaße,P9
"The TCu-380A (AG), MLCu375, and Nova-T IUDs and the IUD daily releasing 20 micrograms levonorgestrel--four pillars of IUD contraception for the nineties and beyond?",Publikation,Chi IC,Contraception,Apr;47(4):325-47,+1993-01-01T00:00:00Z/9,10.1016/0010-7824(93)90031-2,,https://pubmed.ncbi.nlm.nih.gov/8508663/,Kupferspirale,Material des Verhütungsmittels,P5
The multiload IUD--a U.S. researcher's evaluation of a European device,Publikation,Chi IC,Contraception,Nov;46(5):407-25,+1992-01-01T00:00:00Z/9,10.1016/0010-7824(92)90145-j,,https://pubmed.ncbi.nlm.nih.gov/1458888/,Kupferspirale,Material des Verhütungsmittels,P5
Eight years with the same IUD,Publikation,"Bonacho I, Pita S, Gómez-Besteiro MI",Contraception,Apr;59(4):233-6,+1999-01-01T00:00:00Z/9,10.1016/s0010-7824(99)00022-0,,https://pubmed.ncbi.nlm.nih.gov/10457867/,Kupferspirale,Effizienzmaße,P9
Concentrations of copper in human secretions and weight of the copper wire during the 4 to 7 years after insertion of a Cu-IUD (intrauterine device),Publikation,"Larsson B, Frankman O, Hamberger L",Fertil Steril,Dec;36(6):734-6,+1981-01-01T00:00:00Z/9,10.1016/s0015-0282(16)45917-0,,https://pubmed.ncbi.nlm.nih.gov/7308517/,Kupferspirale,Effizienzmaße,P9
One-year results with the Fincoid IUD--a Hungarian experience with the short model,Publikation,Batár I,Adv Contracept,Jun;4(2):137-42,+1988-01-01T00:00:00Z/9,10.1007/BF01849515,,https://pubmed.ncbi.nlm.nih.gov/3213671/,Kupferspirale,Effizienzmaße,P9
The Dimélys IUD,Publikation,"Thiery M, Van Kets H, van der Pas H, Delbarge W, Parewijck W",Adv Contracept,Mar;3(1):43-7,+1987-01-01T00:00:00Z/9,10.1007/BF01849252,,https://pubmed.ncbi.nlm.nih.gov/3307331/,Kupferspirale,Geschlecht,"P3"
Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review,Publikation,"Foran T, Butcher BE, Kovacs G, Bateson D, O'Connor V",Eur J Contracept Reprod Health Care,Oct;23(5):379-386,+2018-01-01T00:00:00Z/9,10.1080/13625187.2018.1526898,Fertility; infection; intrauterine contraceptive devices; intrauterine device complications; intrauterine device expulsion; pain; parity,https://pubmed.ncbi.nlm.nih.gov/30382754/,Kupferspirale,Material des Verhütungsmittels,P5
Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant,Publikation,Croxatto HB,Eur J Contracept Reprod Health Care,Sep;5 Suppl 2:21-8,+2000-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/11246604/,Hormonimplantat (Hormonstäbchen),Geschlecht,"P3"
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials,Publikation,"Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM",Fertil Steril,May;91(5):1646-53,+2009-01-01T00:00:00Z/9,10.1016/j.fertnstert.2008.02.140,,https://pubmed.ncbi.nlm.nih.gov/18423453/,Hormonimplantat (Hormonstäbchen),Effizienzmaße,P10
Management and localization strategies for the nonpalpable Implanon rod,Publikation,"Shulman LP, Gabriel H",Contraception,Apr;73(4):325-30,+2006-01-01T00:00:00Z/9,10.1016/j.contraception.2005.10.009,,https://pubmed.ncbi.nlm.nih.gov/16531160/,Hormonimplantat (Hormonstäbchen),Material des Verhütungsmittels,P5
"A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand",Publikation,"Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ",Eur J Contracept Reprod Health Care,Jun;3(2):85-91,+1998-01-01T00:00:00Z/9,10.3109/13625189809051409,,https://pubmed.ncbi.nlm.nih.gov/9710712/,Hormonimplantat (Hormonstäbchen),Effizienzmaße,P9
A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China,Publikation,"Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF",Eur J Contracept Reprod Health Care,Jun;4(2):85-93,+1999-01-01T00:00:00Z/9,10.3109/13625189909064009,,https://pubmed.ncbi.nlm.nih.gov/10427483/,Hormonimplantat (Hormonstäbchen),Effizienzmaße,P9
A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant,Publikation,"Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF",Contraception,Jul;60(1):1-8,+1999-01-01T00:00:00Z/9,10.1016/s0010-7824(99)00053-0,,https://pubmed.ncbi.nlm.nih.gov/10549446/,Hormonimplantat (Hormonstäbchen),Material des Verhütungsmittels,P5
A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data,Publikation,"Ortayli N, Culwell K, Jackson E, Ali M; WHO Study Group on Contraceptive Implants for Women",Contraception,Jan;87(1):113-20,+2013-01-01T00:00:00Z/9,10.1016/j.contraception.2012.08.044,,https://pubmed.ncbi.nlm.nih.gov/23063337/,Hormonimplantat (Hormonstäbchen),Material des Verhütungsmittels,P5
"Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel",Publikation,"Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, Zampaglione E; Implanon US Study Group",Contraception,May;71(5):319-26,+2005-01-01T00:00:00Z/9,10.1016/j.contraception.2004.11.007,,https://pubmed.ncbi.nlm.nih.gov/15854630/,Hormonimplantat (Hormonstäbchen),Effizienzmaße,P9
"The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant",Publikation,Bennink HJ,Eur J Contracept Reprod Health Care,Sep;5 Suppl 2:12-20,+2000-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/11246602/,Hormonimplantat (Hormonstäbchen),Material des Verhütungsmittels,P5
Estradiol valerate/dienogest: in oral contraception,Publikation,"Hoy SM, Scott LJ",Drugs,Aug 20;69(12):1635-46,+2009-01-01T00:00:00Z/9,10.2165/11202820-000000000-00000,,https://pubmed.ncbi.nlm.nih.gov/19678714/,Kombinierte orale Kontrazeptiva (Pille),Effizienzmaße,P10
Oral contraception over the age of 40,Publikation,Kovacs L,Ann N Y Acad Sci,Nov;997:194-8,+2003-01-01T00:00:00Z/9,10.1196/annals.1290.022,,https://pubmed.ncbi.nlm.nih.gov/14644826/,Kombinierte orale Kontrazeptiva (Pille),Geschlecht,"P3"
"The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel",Publikation,London RS,Obstet Gynecol Surv,Nov;47(11):777-82,+1992-01-01T00:00:00Z/9,10.1097/00006254-199211000-00014,,https://pubmed.ncbi.nlm.nih.gov/1436906/,Kombinierte orale Kontrazeptiva (Pille),Material des Verhütungsmittels,P5
"A single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel",Publikation,"A single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel",Contraception,Mar;89(3):215-21,+2014-01-01T00:00:00Z/9,10.1016/j.contraception.2013.11.013,Levonorgestrel; Pericoital oral contraception; Single-arm study,https://pubmed.ncbi.nlm.nih.gov/24388695/,Kombinierte orale Kontrazeptiva (Pille),Effizienzmaße,P10
Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials,Publikation,"Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Bouchard C, Chen MJ, Apter D, Jost M, Foidart JM, Creinin MD",Contraception,Dec;116:37-43,+2022-01-01T00:00:00Z/9,10.1016/j.contraception.2022.07.009,Combined oral contraception; Contraceptive efficacy; Drospirenone; E4; Estetrol; Native estrogen; Pearl Index,https://pubmed.ncbi.nlm.nih.gov/35921870/,Kombinierte orale Kontrazeptiva (Pille),Effizienzmaße,P10
Oral contraception,Publikation,"Evans G, Sutton EL",Med Clin North Am,May;99(3):479-503,+2015-01-01T00:00:00Z/9,10.1016/j.mcna.2015.01.004,Ethinyl estradiol; Levonorgestrel; Medical eligibility criteria; Oral contraception; Venous thromboembolism,https://pubmed.ncbi.nlm.nih.gov/25841596/,Kombinierte orale Kontrazeptiva (Pille),Geschlecht,"P3"
Ethinylestradiol/dienogest in oral contraception,Publikation,Pérez-Campos EF,Drugs,Apr 16;70(6):681-9,+2010-01-01T00:00:00Z/9,10.2165/11536320-000000000-00000,,https://pubmed.ncbi.nlm.nih.gov/20394455/,Kombinierte orale Kontrazeptiva (Pille),Material des Verhütungsmittels,P5
Types of progestogens in combined oral contraception: effectiveness and side-effects,Publikation,"Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM",Cochrane Database Syst Rev,May 11;(5):CD004861,+2011-01-01T00:00:00Z/9,10.1002/14651858.CD004861.pub2,,https://pubmed.ncbi.nlm.nih.gov/21563141/,Kombinierte orale Kontrazeptiva (Pille),Material des Verhütungsmittels,P5
Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians,Publikation,"Nappi RE, Kaunitz AM, Bitzer J",Eur J Contracept Reprod Health Care,21(2):106-15,+2016-01-01T00:00:00Z/9,10.3109/13625187.2015.1107894,Bleeding; Clinician attitudes; Combined hormonal contraception; Menstrual suppression; Oral contraceptives; Patient satisfaction,https://pubmed.ncbi.nlm.nih.gov/26572318/,Kombinierte orale Kontrazeptiva (Pille),Geschlecht,"P3"
Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature,Publikation,"Palacios S, Regidor PA, Colli E, Skouby SO, Apter D, Roemer T, Egarter C, Nappi RE, Skřivánek A, Jakimiuk AJ, Weyers S, Ács N, Elia D, Gemzell Danielsson K, Bitzer J",Eur J Contracept Reprod Health Care,Jun;25(3):221-227,+2020-01-01T00:00:00Z/9,10.1080/13625187.2020.1743828,Drospirenone; oestrogen-free contraception; progestins; spirolactone derivative,https://pubmed.ncbi.nlm.nih.gov/32312141/,Kombinierte orale Kontrazeptiva (Pille),Material des Verhütungsmittels,P5
Oral contraception: risks and benefits,Publikation,Steinberg WM,Adv Contracept,Dec;5(4):219-28,+1989-01-01T00:00:00Z/9,10.1007/BF01890893,,https://pubmed.ncbi.nlm.nih.gov/2700420/,Kombinierte orale Kontrazeptiva (Pille),Geschlecht,"P3"
Contraception Update: Oral Contraception,Publikation,"Brown EJ, Deshmukh P, Antell K",FP Essent,Nov;462:11-19,+2017-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/29172411/,Kombinierte orale Kontrazeptiva (Pille),Geschlecht,"P3"
Estetrol/Drospirenone: A Review in Oral Contraception,Publikation,"Lee A, Syed YY",Drugs,Jul;82(10):1117-1125,+2022-01-01T00:00:00Z/9,10.1007/s40265-022-01738-8,,https://pubmed.ncbi.nlm.nih.gov/35781795/,Kombinierte orale Kontrazeptiva (Pille),Material des Verhütungsmittels,P5
Contraceptive efficacy and acceptability of the female condom,Publikation,"Farr G, Gabelnick H, Sturgen K, Dorflinger L",Am J Public Health,Dec;84(12):1960-4,+1994-01-01T00:00:00Z/9,10.2105/ajph.84.12.1960,,https://pubmed.ncbi.nlm.nih.gov/7998637/,Kondom für Frauen (Femidom),Effizienzmaße,P9
Effectiveness of the female condom in preventing HIV and sexually transmitted infections: a systematic review and meta-analysis,Publikation,"Wiyeh AB, Mome RKB, Mahasha PW, Kongnyuy EJ, Wiysonge CS",BMC Public Health,Mar 12;20(1):319,+2020-01-01T00:00:00Z/9,10.1186/s12889-020-8384-7,Female condom; HIV; Sexually transmitted infections; Systematic review,https://pubmed.ncbi.nlm.nih.gov/32164652/,Kondom für Frauen (Femidom),Effizienzmaße,P9
The female condom (Femidom)--a study of user acceptability,Publikation,Sapire KE,S Afr Med J,Oct;85(10 Suppl):1081-4,+1995-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8914556/,Kondom für Frauen (Femidom),Geschlecht,"P3"
Comparative contraceptive efficacy of the female condom and other barrier methods,Publikation,"Trussell J, Sturgen K, Strickler J, Dominik R",Fam Plann Perspect,Mar-Apr;26(2):66-72,+1994-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8033980/,Kondom für Frauen (Femidom),Effizienzmaße,P7
The diaphragm with and without spermicide for contraception: a Cochrane review,Publikation,"Cook L, Nanda K, Grimes D",Hum Reprod,Apr;17(4):867-9,+2002-01-01T00:00:00Z/9,10.1093/humrep/17.4.867,,https://pubmed.ncbi.nlm.nih.gov/11925374/,Diaphragma (Pessar),Effizienzmaße,P9
"Effectiveness of the diaphragm, used continuously, without spermicide",Publikation,"Ferreira AE, Araújo MJ, Regina CH, Diniz SG, Faúndes A",Contraception,Jul;48(1):29-35,+1993-01-01T00:00:00Z/9,10.1016/0010-7824(93)90063-d,,https://pubmed.ncbi.nlm.nih.gov/8403903/,Diaphragma (Pessar),Effizienzmaße,P7
"The diaphragm with and without spermicide. A randomized, comparative efficacy trial",Publikation,"Bounds W, Guillebaud J, Dominik R, Dalberth BT",J Reprod Med,Nov;40(11):764-74,+1995-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8592310/,Diaphragma (Pessar),Effizienzmaße,P7
SILCS diaphragm: postcoital testing of a new single-size contraceptive device,Publikation,"Schwartz JL, Ballagh SA, Creinin MD, Rountree RW, Kilbourne-Brook M, Mauck CK, Callahan MM",Contraception,Sep;78(3):237-44,+2008-01-01T00:00:00Z/9,10.1016/j.contraception.2008.04.118,,https://pubmed.ncbi.nlm.nih.gov/18692615/,Diaphragma (Pessar),Material des Verhütungsmittels,P5
"Contraceptive efficacy, safety, fit, and acceptability of a single-size diaphragm developed with end-user input",Publikation,"Schwartz JL, Weiner DH, Lai JJ, Frezieres RG, Creinin MD, Archer DF, Bradley L, Barnhart KT, Poindexter A, Kilbourne-Brook M, Callahan MM, Mauck CK",Obstet Gynecol,Apr;125(4):895-903,+2015-01-01T00:00:00Z/9,10.1097/AOG.0000000000000721,,https://pubmed.ncbi.nlm.nih.gov/25751199/,Diaphragma (Pessar),Effizienzmaße,P10
Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention,Publikation,"Blanchard K, Bostrom A, Montgomery E, van der Straten A, Lince N, de Bruyn G, Grossman D, Chipato T, Ramjee G, Padian N",Contraception,Jun;83(6):556-63,+2011-01-01T00:00:00Z/9,10.1016/j.contraception.2010.10.018,,https://pubmed.ncbi.nlm.nih.gov/21570554/,Kondom für Frauen (Femidom),Effizienzmaße,P9
The female condom,Publikation,McNamee K,Aust Fam Physician,Jun;29(6):555-7,+2000-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/10863812/,Kondom für Frauen (Femidom),Geschlecht,"P3"
"Consistent Condom Use Among Men Who Have Sex With Men in Lomé and Kara, Togo",Publikation,"Ruiseñor-Escudero H, Lyons C, Ketende S, Pitche V, Anato S, Tchalla J, Dometo S, Baral S",AIDS Res Hum Retroviruses,Jun;35(6):519-528,+2019-01-01T00:00:00Z/9,10.1089/AID.2018.0212,HIV; MSM; Togo; behavior; condoms; men who have sex with men,https://pubmed.ncbi.nlm.nih.gov/30714385/,Kondom für Männer,Geschlecht,"P3"
Condom effectiveness,Publikation,Corderoy EC,Fam Plann Perspect,Oct;11(5):271,+1979-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/520506/,Kondom für Männer,Effizienzmaße,P10
Condom effectiveness: where are we now?,Publikation,"Crosby R, Bounse S",Sex Health,Mar;9(1):10-7,+2012-01-01T00:00:00Z/9,10.1071/SH11036,,https://pubmed.ncbi.nlm.nih.gov/22348628/,Kondom für Männer,Effizienzmaße,P9
Condom use errors and problems: a global view,Publikation,"Sanders SA, Yarber WL, Kaufman EL, Crosby RA, Graham CA, Milhausen RR",Sex Health,Mar;9(1):81-95,+2012-01-01T00:00:00Z/9,10.1071/SH11095,,https://pubmed.ncbi.nlm.nih.gov/22348636/,Kondom für Männer,Effizienzmaße,P7
Update on adolescent condom use,Publikation,"Williams RL, Fortenberry JD",Curr Opin Obstet Gynecol,Oct;23(5):350-4,+2011-01-01T00:00:00Z/9,10.1097/GCO.0b013e32834a93bf,,https://pubmed.ncbi.nlm.nih.gov/21825988/,Kondom für Männer,Geschlecht,"P3"
Condom effectiveness in reducing heterosexual HIV transmission,Publikation,"Weller S, Davis K",Cochrane Database Syst Rev,2002(3):CD003255,+2001-01-01T00:00:00Z/9,10.1002/14651858.CD003255,,https://pubmed.ncbi.nlm.nih.gov/11687062/,Kondom für Männer,Effizienzmaße,P9
Can condom users likely to experience condom failure be identified?,Publikation,"Steiner M, Piedrahita C, Glover L, Joanis C",Fam Plann Perspect,Sep-Oct;25(5):220-3,+1993-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/8262171/,Kondom für Männer,Effizienzmaße,P9
Correlates of condom failure in a sexually active cohort of men who have sex with men,Publikation,"Stone E, Heagerty P, Vittinghoff E, Douglas JM Jr, Koblin BA, Mayer KH, Celum CL, Gross M, Woody GE, Marmor M, Seage GR 3rd, Buchbinder SP",J Acquir Immune Defic Syndr Hum Retrovirol,Apr 15;20(5):495-501,+1999-01-01T00:00:00Z/9,10.1097/00042560-199904150-00013,,https://pubmed.ncbi.nlm.nih.gov/10225233/,Kondom für Männer,Geschlecht,"P3"
Comparative evaluation of three Tactylon(TM) condoms and a latex condom during vaginal intercourse: breakage and slippage,Publikation,"Callahan M, Mauck C, Taylor D, Frezieres R, Walsh T, Martens M",Contraception,Mar;61(3):205-15,+2000-01-01T00:00:00Z/9,10.1016/s0010-7824(00)00096-2,,https://pubmed.ncbi.nlm.nih.gov/10827335/,Kondom für Männer,Material des Verhütungsmittels,P5
"Acceptability evaluation of a natural rubber latex, a polyurethane, and a new non-latex condom",Publikation,"Frezieres RG, Walsh TL",Contraception,Jun;61(6):369-77,+2000-01-01T00:00:00Z/9,10.1016/s0010-7824(00)00119-0,,https://pubmed.ncbi.nlm.nih.gov/10958880/,Kondom für Männer,Material des Verhütungsmittels,P5
Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial,Publikation,"Steiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ",Obstet Gynecol,Mar;101(3):539-47,+2003-01-01T00:00:00Z/9,10.1016/s0029-7844(02)02732-1,,https://pubmed.ncbi.nlm.nih.gov/12636960/,Kondom für Männer,Material des Verhütungsmittels,P5
Cervical cap versus diaphragm for contraception,Publikation,"Gallo MF, Grimes DA, Schulz KF",Cochrane Database Syst Rev,(4):CD003551,+2002-01-01T00:00:00Z/9,10.1002/14651858.CD003551,,https://pubmed.ncbi.nlm.nih.gov/12519602/,Portiokappe,Effizienzmaße,P9
The cervical cap,Publikation,Secor RM,NAACOGS Clin Issu Perinat Womens Health Nurs,3(2):236-45,+1992-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/1596432/,Portiokappe,Geschlecht,"P3"
The cervical cap: effectiveness as a contraceptive,Publikation,Boehm D,J Nurse Midwifery,Jan-Feb;28(1):3-6,+1983-01-01T00:00:00Z/9,10.1016/0091-2182(83)90238-0,,https://pubmed.ncbi.nlm.nih.gov/6551434/,Portiokappe,Effizienzmaße,P9
"Contraception with the cervical cap: effectiveness, safety, continuity of use, and user satisfaction",Publikation,"Powell MG, Mears BJ, Deber RB, Ferguson D",Contraception,Mar;33(3):215-32,+1986-01-01T00:00:00Z/9,10.1016/0010-7824(86)90015-6,,https://pubmed.ncbi.nlm.nih.gov/3720304/,Portiokappe,Effizienzmaße,P7
The cervical cap. An alternate barrier contraceptive method,Publikation,"Gilbirds WM 2nd, Jonas HS",Mo Med,Apr;79(4):216-8,+1982-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/7099129/,Portiokappe,Effizienzmaße,P7
Effectiveness of the cavity-rim cervical cap: results of a large clinical study,Publikation,"Richwald GA, Greenland S, Gerber MM, Potik R, Kersey L, Comas MA",Obstet Gynecol,Aug;74(2):143-8,+1989-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/2664609/,Portiokappe,Effizienzmaße,P9
Sponge versus diaphragm for contraception,Publikation,"Kuyoh MA, Toroitich-Ruto C, Grimes DA, Schulz KF, Gallo MF, Lopez LM",Cochrane Database Syst Rev,Jul 22;(5):CD003172,+2002-01-01T00:00:00Z/9,10.1002/14651858.CD003172,,https://pubmed.ncbi.nlm.nih.gov/23866318/,Verhütungsschwamm,Effizienzmaße,P10
The vaginal contraceptive sponge: a new non-prescription barrier contraceptive,Publikation,Lemberg E,Nurse Pract,"Oct;9(10):24-5, 29-32, 37",+1984-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/6387547/,Verhütungsschwamm,Geschlecht,"P3"
Collagen sponge as vaginal contraceptive barrier: critical summary of seven years of research,Publikation,"Chvapil M, Droegemueller W, Heine MW, MacGregor JC, Dotters D",Am J Obstet Gynecol,Feb 1;151(3):325-9,+1985-01-01T00:00:00Z/9,10.1016/0002-9378(85)90296-0,,https://pubmed.ncbi.nlm.nih.gov/2982268/,Verhütungsschwamm,Material des Verhütungsmittels,P5
Parity and use-effectiveness with the contraceptive sponge,Publikation,"McIntyre SL, Higgins JE",Am J Obstet Gynecol,Oct;155(4):796-801,+1986-01-01T00:00:00Z/9,10.1016/s0002-9378(86)80023-0,,https://pubmed.ncbi.nlm.nih.gov/3020983/,Verhütungsschwamm,Effizienzmaße,P10
Updated pregnancy rates for the Today contraceptive sponge,Publikation,"Edelman DA, North BB",Am J Obstet Gynecol,Nov;157(5):1164-5,+1987-01-01T00:00:00Z/9,10.1016/s0002-9378(87)80284-3,,https://pubmed.ncbi.nlm.nih.gov/3318467/,Verhütungsschwamm,Effizienzmaße,P10
Collagen sponge in gynecologic use,Publikation,"Chvapil M, Droegemueller W",Obstet Gynecol Annu,10:363-73,+1981-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/7024877/,Verhütungsschwamm,Material des Verhütungsmittels,P5
Benzalkonium chloride for vaginal contraception--the vaginal sponge,Publikation,"Meyer U, Gerhard I, Runnebaum B",Geburtshilfe Frauenheilkd,Jul;50(7):542-7,+1990-01-01T00:00:00Z/9,10.1055/s-2008-1026298,,https://pubmed.ncbi.nlm.nih.gov/2391020/,Verhütungsschwamm,Material des Verhütungsmittels,P5
Spermicidal and antiviral properties of cholic acid: contraceptive efficacy of a new vaginal sponge (Protectaid) containing sodium cholate,Publikation,"Psychoyos A, Creatsas G, Hassan E, Georgoulias V, Gravanis A",Hum Reprod,Jun;8(6):866-9,+1993-01-01T00:00:00Z/9,10.1093/oxfordjournals.humrep.a138156,,https://pubmed.ncbi.nlm.nih.gov/7688380/,Verhütungsschwamm,Material des Verhütungsmittels,P5
Coitus interruptus. Considerations as a method of birth control,Publikation,Lethbridge DJ,J Obstet Gynecol Neonatal Nurs,Jan-Feb;20(1):80-5,+1991-01-01T00:00:00Z/9,10.1111/j.1552-6909.1991.tb01680.x,,https://pubmed.ncbi.nlm.nih.gov/2005488/,Coitus interruptus,Geschlecht,"P3"
Evaluation of the frequency of coitus interruptus and the effect of contraception counselling on this frequency,Publikation,"Demir O, Ozalp M, Sal H, Aran T, Osmanagaoglu MA",J Obstet Gynaecol,Apr;41(3):453-458,+2021-01-01T00:00:00Z/9,10.1080/01443615.2020.1754370,Fertility control; general gynaecology,https://pubmed.ncbi.nlm.nih.gov/32543257/,Coitus interruptus,Effizienzmaße,P9
Contraceptive withdrawal in adolescents: a complex picture of usage,Publikation,"Woods JL, Hensel DJ, Fortenberry JD",J Pediatr Adolesc Gynecol,Aug;22(4):233-7,+2009-01-01T00:00:00Z/9,10.1016/j.jpag.2008.11.001,,https://pubmed.ncbi.nlm.nih.gov/19646669/,Coitus interruptus,Geschlecht,"P3"
Use of withdrawal and unintended pregnancy among females 15-24 years of age,Publikation,"Dude A, Neustadt A, Martins S, Gilliam M",Obstet Gynecol,Sep;122(3):595-600,+2013-01-01T00:00:00Z/9,10.1097/AOG.0b013e31829d8074,,https://pubmed.ncbi.nlm.nih.gov/23921858/,Coitus interruptus,Geschlecht,"P3"
On the reliability of temperature method for contraception,Publikation,Döring GK,Dtsch Med Wochenschr,Jun 9;92(23):1055-61,+1967-01-01T00:00:00Z/9,10.1055/s-0028-1103790,,https://pubmed.ncbi.nlm.nih.gov/6024685/,Temperaturmethode (Symptothermale Methode),Effizienzmaße,P10
Cervical-mucus and basal body-temperature method of regulating births. Field trial,Publikation,Marshall J,Lancet,Aug 7;2(7980):282-3,+1976-01-01T00:00:00Z/9,10.1016/s0140-6736(76)90732-7,,https://pubmed.ncbi.nlm.nih.gov/59854/,Temperaturmethode (Symptothermale Methode),Effizienzmaße,P10
An updated basal body temperature method,Publikation,"Frank E, White R",Contraception,Nov;54(5):319-21,+1996-01-01T00:00:00Z/9,10.1016/s0010-7824(96)00187-4,,https://pubmed.ncbi.nlm.nih.gov/8934068/,Temperaturmethode (Symptothermale Methode),Geschlecht,"P3"
The rhythm method of contraception,Publikation,Porter JF,Reprod Fertil Suppl,Apr;(22):91-105,+1975-01-01T00:00:00Z/9,,,https://pubmed.ncbi.nlm.nih.gov/1058971/,Kalendermethode,Geschlecht,"P3"
Alternatives to vaginal intercourse practiced during the fertile time among calendar method users in Ireland,Publikation,"Bonnar J, Lamprecht V, O'Conner E",Adv Contracept,Jun-Sep;13(2-3):173-7,+1997-01-01T00:00:00Z/9,10.1023/a:1006599804380,,https://pubmed.ncbi.nlm.nih.gov/9288335/,Kalendermethode,Geschlecht,"P3"
"Periodic abstinence and calendar method use in Hungary, Peru, the Philippines, and Sri Lanka",Publikation,"d'Arcangues C, Kennedy KI; Research Group on Methods for the Natural Regulation of Fertility",Contraception,Oct;64(4):209-15,+2001-01-01T00:00:00Z/9,10.1016/s0010-7824(01)00252-9,,https://pubmed.ncbi.nlm.nih.gov/11747869/,Kalendermethode,Geschlecht,"P3"
Pioneering studies of the 'morning-after' pill,Publikation,Kunjappu MJ,Yale J Biol Med,Jun;84(2):109-11,+2011-01-01T00:00:00Z/9,,'morning-after' pill; diethylstilbestrol; emergency contraception; estrogenic compounds; ethinyl estradiol,https://pubmed.ncbi.nlm.nih.gov/21698041/,Pille Danach,Geschlecht,"P3"
The morning-after pill--how long after?,Publikation,"Grou F, Rodrigues I",Am J Obstet Gynecol,Dec;171(6):1529-34,+1994-01-01T00:00:00Z/9,10.1016/0002-9378(94)90396-4,,https://pubmed.ncbi.nlm.nih.gov/7802062/,Pille Danach,Geschlecht,"P3"
Emergency contraception - A review,Publikation,"Rudzinski P, Lopuszynska I, Pazik D, Adamowicz D, Jargielo A, Cieslik A, Kosieradzka K, Stanczyk J, Meliksetian A, Wosinska A",Eur J Obstet Gynecol Reprod Biol,Dec;291:213-218,+2023-01-01T00:00:00Z/9,10.1016/j.ejogrb.2023.10.035,Copper intrauterine device; Emergency contraception; Levonorgestrel; Postcoital contraception; Ulipristal acetate,https://pubmed.ncbi.nlm.nih.gov/37922775/,Pille Danach,Geschlecht,"P3"
Emergency Contraception,Publikation,"Batur P, Kransdorf LN, Casey PM",Mayo Clin Proc,Jun;91(6):802-7,+2016-01-01T00:00:00Z/9,10.1016/j.mayocp.2016.02.018,,https://pubmed.ncbi.nlm.nih.gov/27261868/,Pille Danach,Geschlecht,"P3"
Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial,Publikation,"Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY",Lancet,Sep 9;402(10405):851-858,+2023-01-01T00:00:00Z/9,10.1016/S0140-6736(23)01240-0,,https://pubmed.ncbi.nlm.nih.gov/37597523/,Pille Danach,Effizienzmaße,P9
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis,Publikation,"Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E",Lancet,Feb 13;375(9714):555-62,+2010-01-01T00:00:00Z/9,10.1016/S0140-6736(10)60101-8,,https://pubmed.ncbi.nlm.nih.gov/20116841/,Pille Danach,Effizienzmaße,P9
Mechanisms of action of oral emergency contraception,Publikation,"Gemzell-Danielsson K, Berger C, Lalitkumar PG",Gynecol Endocrinol,Oct;30(10):685-7,+2014-01-01T00:00:00Z/9,10.3109/09513590.2014.950648,Emergency contraception pills; endometrium; follicular development; implantation; levonorgestrel; ovulation; ulipristal acetate,https://pubmed.ncbi.nlm.nih.gov/25117156/,Pille Danach,Material des Verhütungsmittels,P5
Current controversies with oral emergency contraception,Publikation,"Cameron ST, Li H, Gemzell-Danielsson K",BJOG,Dec;124(13):1948-1956,+2017-01-01T00:00:00Z/9,10.1111/1471-0528.14773,Emergency contraception; levonorgestrel; postcoital contraceptive agents; ulipristal acetate,https://pubmed.ncbi.nlm.nih.gov/28658565/,Pille Danach,Material des Verhütungsmittels,P5